• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    VivoSim Labs, Inc. - Common Stock (NQ:VIVS)

    0.2202 -0.0038 (-1.70%)
    Streaming Delayed Price Updated: 3:59 PM EDT, Sep 28, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about VivoSim Labs, Inc. - Common Stock

    < Previous 1 2 Next >
    News headline image
    2026 Nanocap Stocks to Watch: IGC, KNRX, GYGY, ARAY Lead Watchlist Now See More Inside!
    Via AB Newswire
    Topics Artificial Intelligence
    News headline image
    VivoSim Labs Inc. (NASDAQ: VIVS) Targets the Multibillion-Dollar Cost of Failed Drugs
    Via AB Newswire
    News headline image
    Greenland Stocks in Focus: GLND, GRML, CRML Lead the Watchlist More Names Inside
    Via AB Newswire
    Topics Government
    News headline image
    VivoSim Labs Inc. (NASDAQ: VIVS) Takes Aim at Pharma’s 92% Drug-Failure Problem
    Via AB Newswire
    Topics Animal Testing
    News headline image
    High-Impact Stocks DRK, VIVS, AEMD, GMG in the News
    Via AB Newswire
    Topics Artificial Intelligence Energy
    News headline image
    VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs
    New data presented in Vienna highlights long-term repeat-dose modeling, mechanistic GI barrier profiling, and deconvolution of payload- and linker-dependent toxicities for complex modalities 
    From VivoSim Labs, Inc.
    Via GlobeNewswire
    News headline image
    Catch the Danger, Spare the Cure: Why VivoSim’s (NASDAQ: VIVS) 90%/95% Toxicity Results Matter
    Via AB Newswire
    Topics Artificial Intelligence
    News headline image
    VivoSim Labs (NASDAQ: VIVS): Predicting Drug Toxicity Before Human Clinical Trials
    Via AB Newswire
    News headline image
    VivoSim Labs (NASDAQ: VIVS) Opens New Pharma Opportunity
    Via AB Newswire
    News headline image
    Microcaps GPRO, FLYE, HKPD, VIVS to Watch Now
    Via AB Newswire
    Topics Artificial Intelligence Supply Chain
    News headline image
    VivoSim Labs to Add Rat Liver Model to NAMkind Platform
    New cross-species capability is designed to help pharma distinguish rat-specific liver toxicity from risks that may translate to humans 
    From VivoSim Labs, Inc.
    Via GlobeNewswire
    News headline image
    IGC Pharma (NYSE: IGC) Target Raised on Alzheimer’s 2027 Outlook
    Via AB Newswire
    Topics Artificial Intelligence
    News headline image
    VivoSim Labs (NASDAQ: VIVS): 10,000 Compounds to 1 Drug with AI-Powered 3D Human Toxicology
    Via AB Newswire
    Topics Artificial Intelligence
    News headline image
    Nasdaq 30’s VIVS, IGC, RIME, AIXI Stocks Now
    Via AB Newswire
    Topics Artificial Intelligence
    News headline image
    VivoSim Labs (NASDAQ: VIVS) Research Report Highlights AI-Powered Drug Toxicity Platform, FDA NAM Momentum
    Via AB Newswire
    Topics Animal Testing Artificial Intelligence
    News headline image
    VivoSim Labs (NASDAQ: VIVS) Among IGC, OSRH, IVF as FDA-Backed Human-Based Testing Gains Momentum
    Via AB Newswire
    Topics Animal Testing Artificial Intelligence
    News headline image
    VivoSim Labs (NASDAQ: VIVS) Emerges in Drug Toxicity Market as Revenue Growth Guidance Tops 500% – Plus More In Focus
    Via AB Newswire
    Topics Animal Testing Artificial Intelligence
    News headline image
    Oversold Stocks TOON, RMCF, PRSO, OFAL Offer Opportunity – See Why Inside
    Via AB Newswire
    Topics Artificial Intelligence
    News headline image
    VivoSim Provides Financial and Listing Compliance Update
    From VivoSim Labs, Inc.
    Via GlobeNewswire
    In today's session, these stocks are experiencing unusual volume. ↗
    Via Chartmill
    MissionIRNewsBreaks – VivoSim Labs, Inc. (NASDAQ: VIVS) Announces $4 Million Private Placement
    Via Investor Brand Network
    Topics Animal Testing
    News headline image
    VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services
    Initial customer wins bring VivoSim’s human-relevant liver and GI testing to the world’s second-largest pharmaceutical market 
    From VivoSim Labs, Inc.
    Via GlobeNewswire
    In today's session, these stocks are experiencing unusual volume. ↗
    Via Chartmill
    Thursday's session: top gainers and losers ↗
    Via Chartmill
    There are notable gap-ups and gap-downs in today's session. ↗
    Via Chartmill
    News headline image
    VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor
    From VivoSim Labs, Inc.
    Via GlobeNewswire
    News headline image
    VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027
    From VivoSim Labs, Inc.
    Via GlobeNewswire
    News headline image
    VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting
    VivoSim Demonstrates Leadership in Field through AI-enabled NAMkind™ Liver and Intestine with High Accuracy Results, Including for Antibody Drug Conjugates (ADCs) 
    From VivoSim Labs, Inc.
    Via GlobeNewswire
    News headline image
    VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing
    VivoSim’s NAMkind™ Intestinal Model combined with AI prediction tools yields high-accuracy results 
    From VivoSim Labs, Inc.
    Via GlobeNewswire
    Which stocks are moving before the opening bell on Wednesday? ↗
    Via Chartmill
    < Previous 1 2 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.